Ipca Laboratories Ltd. (NSE: IPCALAB, BSE: 524494) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹49,178 Cr, it ranks #211 by market cap among the 6,197 Indian listed companies on FinBizNet, and #12 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,889.90 (as of 16 Nov 2026), the share price is 7.3% below its 52-week high of ₹2,038.00 and 38.8% above its 52-week low of ₹1,361.70. The share price is up 44.4% over one year and up 4.9% over three months.
| Current Price | ₹1,889.90 |
|---|---|
| Market Cap | ₹49,178 Cr |
| NSE Symbol | IPCALAB |
| BSE Code | 524494 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 42.4 |
| Return on Equity | 13.22% |
| Return on Assets | 8.42% |
| 52-Week Range | ₹1,361.70 – ₹2,038.00 |
| 1-Year Price Change | +44.4% |
| 3-Month Price Change | +4.9% |
| Beta (1Y) | -0.02 |
| Dividend Yield | 0.31% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.ipca.com |
| Revenue | ₹2,910 Cr |
|---|---|
| Net Profit | ₹389 Cr |
| Net Margin | 13.4% |
| EPS (Basic) | ₹14.79 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ipca Laboratories Ltd. reported revenue of ₹2,910 Cr in Q2 FY27, up 13.8% from ₹2,557 Cr in Q2 FY26 and up 4.4% from ₹2,788 Cr in Q1 FY27. It posted a net profit of ₹389 Cr for the quarter, against a net profit of ₹281 Cr in Q2 FY26 (up 38.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,247 Cr (Q4 FY25) to ₹2,910 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,910 Cr | ₹389 Cr | 13.4% |
| Q1 FY27 | ₹2,788 Cr | ₹424 Cr | 15.2% |
| Q4 FY26 | ₹2,388 Cr | ₹307 Cr | 12.8% |
| Q3 FY26 | ₹2,393 Cr | ₹364 Cr | 15.2% |
| Q2 FY26 | ₹2,557 Cr | ₹281 Cr | 11.0% |
| Q1 FY26 | ₹2,309 Cr | ₹233 Cr | 10.1% |
| Q4 FY25 | ₹2,247 Cr | ₹64 Cr | 2.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 44.72% of Ipca Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 55.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products
1. Pharmaceuticals-This segment manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients for various therapeutic segments.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Ipca Laboratories Ltd. | ₹49,178 Cr | 42.4 | 13.22% | ₹2,910 Cr | +44.4% |
Listed by market capitalisation. Ratios are shown for context only.
Ipca Laboratories Ltd. is trading at ₹1,889.90, with a market capitalisation of ₹49,178 Cr.
Ipca Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ipca Laboratories Ltd. has a P/E of 42.4 and a return on equity of 13.22%.
Ipca Laboratories Ltd. is listed on the NSE under the symbol IPCALAB and on the BSE under the scrip code 524494.
Ipca Laboratories Ltd.'s share price is up 44.4% over one year and up 4.9% over three months. Its 52-week range is ₹1,361.70 to ₹2,038.00.
In Q2 FY27, Ipca Laboratories Ltd. reported revenue of ₹2,910 Cr and net profit of ₹389 Cr, with basic EPS of ₹14.79 (consolidated, parsed from the company's exchange filing).
Ipca Laboratories Ltd. reported revenue of ₹2,910 Cr in Q2 FY27, up 13.8% from ₹2,557 Cr in Q2 FY26 and up 4.4% from ₹2,788 Cr in Q1 FY27.
Promoters held 44.72% of Ipca Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.